Navigation Links
Harvard scientists control cells following transplantation, from the inside out
Date:1/10/2014

Harvard stem cells scientists at Brigham and Women's Hospital and MIT can now engineer cells that are more easily controlled following transplantation, potentially making cell therapies, hundreds of which are currently in clinical trials across the United States, more functional and efficient.

Associate Professor Jeffrey Karp, PhD, and James Ankrum, PhD, demonstrate in this month's issue of Nature Protocols how to load cells with microparticles that provide the cells cues for how they should behave over the course of days or weeks as the particles degrade.

"Regardless of where the cell is in the body, it's going to be receiving its cues from the inside," said Karp, a Harvard Stem Cell Institute Principal Faculty member at Brigham and Women's Hospital. "This is a completely different strategy than the current method of placing cells onto drug-doped microcarriers or scaffolds, which is limiting because the cells need to remain in close proximity to those materials in order to function. Also these types of materials are too large to be infused into the bloodstream."

Cells are relatively simple to control in a Petri dish. The right molecules or drugs, if internalized by a cell, can change its behavior; such as inducing a stem cell to differentiate or correcting a defect in a cancer cell. This level of control is lost after transplantation as cells typically behave according to environmental cues in the recipient's body. Karp's strategy, dubbed particle engineering, corrects this problem by turning cells into pre-programmable units. The internalized particles stably remain inside the transplanted cell and tell it exactly how to act, whether the cell is needed to release anti-inflammatory factors or regenerate lost tissue.

"Once those particles are internalized into the cells, which can take on the order of 6-24 hours, we can deliver the transplant immediately or even cryopreserve the cells," Karp said. "When the cells are thawed at the patient's bedside, they can be administered and the agents will start to be released inside the cells to control differentiation, immune modulation or matrix production, for example."

It could take more than a decade for this type of cell therapy to be a common medical practice, but to speed up the pace of research, Karp published the Nature Protocols study to encourage others in the scientific community to apply the technique to their fields. The paper shows the range of different cell types that can be particle engineered, including stem cells, immune cells, and pancreatic cells.

"With this versatile platform, which leveraged Harvard and MIT experts in drug delivery, cell engineering, and biology, we've demonstrated the ability to track cells in the body, control stem cell differentiation, and even change the way cells interact with immune cells," said Ankrum, a former graduate student in Karp's laboratory. "We're excited to see what applications other researchers will imagine using this platform."


'/>"/>

Contact: Joseph Caputo
joseph_caputo@harvard.edu
914-573-1784
Harvard University
Source:Eurekalert  

Related biology news :

1. Harvards Wyss Institute to develop smart suit that improves soldiers physical endurance
2. Got to go? Harvard scientists figure out how you know
3. Renewed Harvard-BASF initiative to advance functional materials
4. Harvards Wyss Institute and Sony DADC announce collaboration on Organs-on-Chips
5. Harvard and USC scientists show how DHA resolves inflammation
6. Harvard Stem Cell researchers create cells that line blood vessels
7. "GenoVive is changing the face of personalized health by continuing research efforts with Harvard."
8. Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors
9. Harvard study shows sprawl threatens water quality, climate protection, and land conservation gains
10. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
11. Queens scientists seek vaccine for Pseudomonas infection
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Harvard scientists control cells following transplantation, from the inside out
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, ... Simple," and 23andMe , the leading personal genetics ... choices.  Zipongo can now provide customers with personalized nutrition ... goals and biometrics, but also genetic markers impacting how ... Zipongo,s personalized food decision support platform uses biometrics ...
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... 24, 2017 Agenus Inc. (NASDAQ: AGEN), an ... and cancer vaccines, today announced participation at the following ... William Blair and Maidstone Life Sciences conference "Cancer Immunotherapy ... New York, NY . Agenus will ... at 9:40 am: Robert B. Stein , M.D., ...
(Date:3/23/2017)... , March 23, 2017  Northwest Biotherapeutics ... DCVax® personalized immune therapies for solid tumor cancers, ... $7.5 million financing it announced last Friday, March ... to several institutional investors securities totaling 28,843,692 shares, ... share, and 10,000,000 shares of Class C Warrants ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company Cool ... financing and note conversion to commercialize its Cool Terra ... focused on developing products that are simultaneously profitable as ... in the last 18 months. This latest round of ... Venture Partners. The company,s primary product, ...
Breaking Biology Technology: